University of Texas Medical Branch selects Symvess for surgical advances, Humacyte reports

University of Texas Medical Branch selects Symvess for surgical advances, Humacyte reports
Texas Medical adopts Symvess

Humacyte announced that the University of Texas Medical Branch has become the first health system in the Greater Houston metropolitan area to implement its Symvess product.

The company also recognized the surgical team, including Dr. Mitchell Cox and Dr. Eric Whittington, for achieving a series of notable milestones. This development marks a new customer deployment and highlights the expanding clinical adoption of Symvess within key regional medical institutions.

Humacyte recently announced plans to present interim Phase 3 V012 results of ATEV for hemodialysis access in women at Kidney Week. The company has also shared outcomes from its Phase 3 trial in women needing hemodialysis access, scheduled for presentation at ASN Kidney Week 2026 here. These developments follow continued efforts to advance clinical use of its vascular products.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.